Efficacy of the Vaccines, Their Safety, and Immune Responses against SARS-CoV-2 Infections

Mahendra Pal^1, and Kirubel Paulos Gutama²

¹Narayan Consultancy on Veterinary Public Health and Microbiology, Anand, India

²Adaba Woreda Livestock and Fishery Resource Development Office, West Arsi, Ethiopia

Cite this paper:
Mahendra Pal and Kirubel Paulos Gutama. Efficacy of the Vaccines, Their Safety, and Immune Responses against SARS-CoV-2 Infections. American Journal of Microbiological Research. 2021; 9(4):103-106. doi: 10.12691/ajmr-9-4-1

Abstract

The search for vaccines has been a high priority since the worldwide COVID-19 pandemic was declared. Currently, mRNA-based vaccines, adenovirus-based vaccines, inactivated virus vaccines, and other vaccine platforms are all employed to combat the SARS-CoV-2 virus. BNT162b2 and mRNA-1273 are mRNA-based vaccines. The vaccination appears to be effective against SARS-CoV-2 strains that have emerged since the first study. They have primarily minor side effects, and there are no major safety concerns. Adenovirus-based vaccines are delivered by genetic cargo that is based on non-replicating adenovirus vectors that can increase immune response without the need of adjuvants. This is the case for Ad26.CoV2.S, ChAdOx1 nCoV-19/AZD1222, Gam-COVID-Vac/Sputnik V andAd5-based COVID-19 vaccine. There have been no known incidences of allergy to adenovirus vaccines, unlike mRNA vaccines. Inactivated virus vaccines are a common form of vaccine that has been used for decades. The goal is to render the virus non-infectious while preserving immunogenicity with high-quality antigens in order to trigger an immune response. The researched formaldehyde-inactivated whole-virus SARS-CoV2 vaccine (CoronaVac), as well as WIV04 and HB02, utilize this sort of vaccine formulation. A recombinant protein nanoparticle vaccine named NVX-CoV2373 is made up of trimeric spike glycoproteins with a potent Matrix-M1 adjuvant. Against the variant B.1.1.7 (Alpha), the vaccine appeared to be very effective. Vaccine efficacy against the B.1.351 (Beta) strain, on the other hand, proved to be lower.

Keywords:
COVID-19 efficacy immune response safety vaccines

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Callegaro, A., Borleri, D., Farina, C., et al. Antibody response to SARS-CoV-2. Journal of Medical Virology, 93: 4612-4615. 2021.
[2]	Pal, M., Kerosa, G. B. and Kandi, R. A knowledge update on SARS-Coronavirus-2 (SARS-CoV-2)/COVID-19 and its global public health implications. American Journal of Clinical Medicine Research, 8: 48-56. 2020.
[3]	Pal, M., Bulcha, M.R., Banu, W. M. and Ketchakmadze, D. SARS-CoV-2 (COVID-19) pandemic remains a global threat. Iberoamericana Journal of Medicine, 3: 264-270. 2021.
[4]	World Health Organization (WHO). (2021). Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. (Accessed August, 2021).
[5]	Xiao, Y. and Torok, M.E. Taking the right measures to control COVID-19. Lancet Infectious Disease, 20: 523-4. 2020.
[6]	Gerberding J.L. and Haynes B.F. Vaccine innovations-past and future. New England Journal of Medicine, 384: 393-6. 2021.
[7]	Su, Z., Yang, Z., Xie, L. et al. Cancer therapy in the necroptosis era. Cell Death and Differentiation, 23:748–756. 2016.
[8]	Krammer, F. SARS-CoV-2 vaccines in development. Nature, 586: 516-527. 2020.
[9]	Castells, M.C. and Phillips, E.J. Maintaining safety with SARS-CoV-2 vaccines. New England Journal of Medicine, 384: 643-9. 2021.
[10]	Pascolo, S. Synthetic messenger RNA-based vaccines: from Scorn to Hype. Viruses, 13: 270. 2021.
[11]	García-Montero, C., Fraile-Martínez, O., Bravo, C. et al. An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines, 9: 433. 2021.
[12]	Kowalczyk, A., Doener, F., Zanzinger, K. et al. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine, 34: 3882-3893. 2016.
[13]	Knezevic, I., Liu, M., Peden, K., Zhou, T. and Kang, H. Development of mRNA vaccines: Scientific and regulatory issues. Vaccines, 9:81. 2021.
[14]	Creech, C.B., Walker, S.C. and Samuels, R.J. SARS-CoV-2. Vaccines, 325:1318-1320. 2021.
[15]	Polack, F.P., Thomas, S.J., Kitchin, N. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383:2603–2615. 2020.
[16]	US Food and Drug Administration (FDA). (2020). Fact sheet for healthcare providers administering vaccine: Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019. https://www.fda.gov/media/146304/download. (Accessed August, 2021).
[17]	Baden, L.R., El sahly, H.M., Essink, B. et al. Efficacy and safety of Mrna-1273 SARS-CoV-2 vaccine. New England Journal of Medicine, 384:403. 2021.
[18]	Pilishvili, T., Fleming-Dutra, K.E., Farray, J.L. et al. Interim estimates of vaccines effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel-33 U.S. sites. Morbidity and Mortality Weekly Report, 70:753. 2021.
[19]	Thompson, M.G., Burgess, J.L., Naleway, A.L. et al. Prevention and attenuation of Covid-19 with the BNT162b2 and Mrna-1273 vaccine. New England Journal of Medicine, 385:320. 2021.
[20]	Tenforde, M.W., Olson, S.M., Self, W.H. et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged >65 years-U.S. Morbidity and Mortality Weekly Report, 65;344. 2021.
[21]	Gregory, A.P., Inna, G.O. and Richard, B.K. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet, 396: 1595-606. 2020.
[22]	Tatsis, N. and Ertl, H.C. Adenoviruses as vaccine vectors. Molecular Therapy, 4: 616-29. 2004.
[23]	Zhu, F.C., Guan, X.H., Li, Y.H. et al. Immunogenecity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double blind, placebo-controlled, phase 2 trial. Lancet, 396: 479. 2020.
[24]	Sputnik Vaccine. (2021). The Gamaleya Center statement on increasing the interval between the first and second Sputnik V vaccine shots. https://sputnikvaccine.com/newsroom/pressreleases/the-gamaleya-center-statement-on-increasing-the-interval-between-first-and-second-sputnik-v-vaccine-/ (Accessed on August, 2021).
[25]	Lee, C.S., Bishop, E.S., Zhang, R. et al. Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Disease, 4: 43-63. 2017.
[26]	Sadoff, J., Gray, G., Vandesbosch, A. et al. Safety and efficacy of single-dose AD26.COV2.S vaccine against Covid-19. New England Journal of Medicine, 384: 2187. 2021.
[27]	Zhang, Y., Zeng, G. and Pan, H. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Disease, 21: 181-192. 2021.
[28]	AstraZeneca. (2021). AZD1222 US Phase III primary analysis confirms safety and efficacy. 2021. Available: https://www.astrazeneca.com/content/astraz/media-centre/press releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy. (Accessed on July, 2021).
[29]	Clinical Trials. Gov. (2021). Phase III trial of a COVID-19 vaccine of Adenovirus vector in adults 18 years old and above. 2021. Available online: https://clinicaltrials.gov/ct2/show/NCT04526990. (Accessed on July, 2021).
[30]	Logunov, D.Y., Dolzhikova, I.V. and Shcheblyakov, D.V. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 397: 671-681. 2021.
[31]	Gao, Q., Bao, L., Mao, H., et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science, 369: 77-81. 2020.
[32]	Xia, S., Duan, K., Zhang, Y., et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. Lancet Infectious Disease, 324: 951. 2020.
[33]	Xia, S., Zhang, Y., Wang, Y., et al. Safety and immunogenicity of an Inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A Randomised, double-blind, placebo-controlled, phase1/2 trial. Lancet Infectious Disease, 21: 39. 2021.
[34]	Soleimanpour, S. and Yaghoubi, A. COVID-19 vaccine: Where are we now and where should we go? .Expert Review. Vaccines, 20: 23-44. 2021.
[35]	Zhang, Y.J., Zeng, G., Pan, H.X., et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: Report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. Medical, 1216: 342-346. 2020.
[36]	Canedo-Marroquín, G., Saavedra, F., Andrade, C.A., et al. SARS-CoV-2: Immune response elicited by infection and development of vaccines and treatments. Frontier Immunology, 11: 56-60. 2020.
[37]	Kabi, A., Kaeley, N., Shankar, T. et al. (September 04, 2021) COVID-19-Associated pneumomediastinum and pneumothorax: A case series. Cureus, 13: e17715. 2021.
[38]	Tanriover, M.D., Doğanay, H.L., Akova, M., et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet, 398: 213-222. 2021.
[39]	Palacios, R., Batista, A.P and Albuquerque, C.S.N. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study. SSRN, 2021.
[40]	Wu, Z., Hu, Y., Xu, M., et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Disease, 387: 124-127. 2021.
[41]	Yan, Z.P., Yang, M. and Lai, C.L. COVID-19 Vaccines: A review of the safety and efficacy of current clinical trials. Pharmaceuticals, 14: 406. 2021.
[42]	Keech, C., Albert, G., Cho, I., et al. Phase 1-2 trial of SARS-CoV-2 recombinant spike protien nanoparticle vaccine. New England Journal of Medicine, 383: 2320. 2020.
[43]	Novavax. (2020). Novavax COVID-19 Vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in prevent-19 phase 3 trial. 2021. https://ir.novavax.com/2021-06-14-Novavax-COVID-19-vaccine-demonstrates-90-overall-efficacy-and-100-protection-against-moderate-and-severe-disease-in-prevent-19-phase-3-trial. (Accessed on August, 2021).
[44]	Heath, P.T., Galiza, E.P., Baxter, D.N., et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine, 384: 127-132. 2021.
[45]	Shinde, V., Bhikha, S., Hoosain, Z., et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine, 384:1899. 2021.